COST EFFECTIVENESS OF OVERACTIVE BLADDER TREATMENT WITH MIRABEGRON IN PATIENTS IN SOUTH KOREA

被引：0
|
作者：
Suh, D. [1 ]
Lee, S. [1 ]
Lim, S. J. [1 ]
Song, J. [1 ]
Ko, G. [2 ]
机构：
[1] Chung Ang Univ, Seoul, South Korea
[2] Astellas Pharma Inc, Seoul, South Korea
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.08.502
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PUK8
引用
收藏
页码：A847 / A847
页数：1
相关论文
共 50 条
  • [21] Cost effectiveness of Mirabegron and antimuscarinic drugs in patients with hiperactive bladder
    Arlandis-Guzman, Salvador
    Brenes-Bermudez, Francisco
    Jimenez-Cidre, Miguel A.
    Rubio-Rodriguez, Dario
    Rubio-Terres, Carlos
    Moray, Ana Ma
    Duran, Aurea
    ARCHIVOS ESPANOLES DE UROLOGIA, 2018, 71 (10): : 809 - 824
  • [22] COST-EFFECTIVENESS OF MIRABEGRON 50MG COMPARED TO TOLTERODINE ER 4MG IN THE TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER IN CANADA
    Herschorn, S.
    Vicente, C.
    Nazir, J.
    Ramos, B.
    Hakimi, Z.
    VALUE IN HEALTH, 2014, 17 (07) : A469 - A469
  • [23] COST-UTILITY ANALYSIS OF MIRABEGRON VERSUS ANTIMUSCARINIC THERAPY IN THE TREATMENT OF OVERACTIVE BLADDER
    Majd, Karimi Z.
    Taheri, S.
    Yousefi, N.
    Peiravian, F.
    VALUE IN HEALTH, 2019, 22 : S915 - S916
  • [24] Hormonal influence on the effect of mirabegron treatment for overactive bladder
    Kallner, Helena Kopp
    Elmer, Caroline
    Andersson, Karl-Erik
    Altman, Daniel
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2016, 23 (12): : 1303 - 1306
  • [25] Profile of mirabegron in the treatment of overactive bladder: place in therapy
    Sharaf, Ala'a
    Hashim, Hashim
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 663 - 667
  • [26] Effectiveness and persistence of mirabegron as a first-line treatment in patients with overactive bladder in real-life practice
    Shin, Jung Hyun
    Choo, Myung-Soo
    LUTS-LOWER URINARY TRACT SYMPTOMS, 2019, 11 (03) : 151 - 157
  • [27] Mirabegron approved for overactive bladder
    Traynor, Kate
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2012, 69 (15) : 1270 - 1270
  • [28] THE USE OF MIRABEGRON IN THE TREATMENT OF OVERACTIVE BLADDER IN PATIENTS AFFECTED BY PARKINSON'S DISEASE
    Gubbiotti, Marilena
    de Vermandois, Jacopo Adolfo Rossi
    Turco, Morena
    Salvini, Eleonora
    Cagini, Roberta
    Giannantoni, Antonella
    NEUROUROLOGY AND URODYNAMICS, 2017, 36 : S82 - S83
  • [29] Mirabegron (Myrbetriq) for Overactive Bladder
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2013, 55 (1410): : 13 - 15
  • [30] Mirabegron for the treatment of overactive bladder: cost-effectiveness from US commercial health-plan and Medicare Advantage perspectives
    Wielage, Ronald C.
    Perk, Sinem
    Campbell, Noll L.
    Klein, Timothy M.
    Posta, Linda M.
    Yuran, Thomas
    Klein, Robert W.
    Ng, Daniel B.
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (12) : 1135 - 1143
12345